http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201411132-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae10212794160b34478f0d05b6ab6fd7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2013-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7f2b0198d1bf063e333220537ff701b |
| publicationDate | 2014-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-201411132-A |
| titleOfInvention | Resistant biomarkers for HDAC inhibitors |
| abstract | The present invention provides a method of identifying a cancer patient at risk of developing resistance to HDAC inhibitor therapy comprising obtaining a tumor sample from the cancer patient; detecting the presence of testicular specific Y-like protein 5 (TSPYL5) in the sample Quantifying the amount of expression of the TSPYL5 in the sample, wherein the high expression level of the TSPYL5 is related to the resistance to the HDAC inhibitor therapy relative to the established performance threshold of the TSPYL5; and applying the correlation to identify the HDAC Inhibitor therapy has this cancer patient at risk of developing resistance. Also provided is a method of identifying a cancer patient with an increased likelihood of a positive clinical response to HDAC inhibitor therapy comprising obtaining a tumor sample from the cancer patient; detecting testicular specific Y-encoded protein 5 (TSPYL5) in the sample Existence of performance; quantifying the amount of expression of the TSPYL5 in the sample, wherein the low performance of the TSPYL5 relative to the established performance threshold of the TSPYL5 identifies an increased likelihood of a positive clinical response to the HDAC inhibitor therapy cancer patient. Related methods and compositions are also provided. |
| priorityDate | 2012-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 221.